Allspring Global Investments
ABCL icon

Allspring Global Investments’s AbCellera Biologics ABCL Stock Holding History

Allspring Global Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,877
Closed -$240K – 2686
2023
Q1 		$240K Sell
31,877
-82,883
-72% -$753K ﹤0.01% 1774
2022
Q4 		$1.16M Sell
114,760
-1,674
-1% -$19.3K ﹤0.01% 1396
2022
Q3 		$1.15M Buy
+116,434
New +$1.28M ﹤0.01% 1400

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Allspring Global Investments's ABCL Position: Q2 2023 in Review

Allspring Global Investments sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 31,877 shares — an estimated $240K sold.

Allspring Global Investments first reported a position in ABCL in Q3 2022 and held it in 3 quarters. The position peaked at $1.16M in Q4 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Allspring Global Investments reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Allspring Global Investments sold 31,877 AbCellera Biologics shares in Q2 2023, an estimated $240K.
  • Allspring Global Investments first reported a position in AbCellera Biologics in Q3 2022 and held it in 3 quarters.
  • Allspring Global Investments's AbCellera Biologics position peaked at $1.16M in Q4 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.